Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.70 |
| ▸ | HTR2C | P28335 | 9/20 | 0.68 |
| ▸ | QDPR | P09417 | 3/20 | 0.56 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043133 | 0.85 | SCN9A (0.61) | SIGMAR1HTR2CQDPRSCN9AHTR2A | |
| SCHEMBL3899585 | 0.83 | SIGMAR1 (0.92) | SIGMAR1HTR2CQDPRHTR2AHTR6 | |
| SCHEMBL415545 | 0.83 | SIGMAR1 (1.00) | SIGMAR1HTR2CQDPRHTR2AHTR6 | |
| Bromide SCHEMBL11385943 | 0.81 | SIGMAR1 (0.96) | SIGMAR1HTR2CQDPRHTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL446973 | 0.81 | HTR2C (1.00) | SIGMAR1HTR2CQDPRHTR2AHTR6 | |
| SCHEMBL4672600 | 0.80 | PRMT5 (0.64) | SIGMAR1HTR2CQDPRHTR6 | |
| Hydrochloric Acid SCHEMBL3676212 | 0.80 | SIGMAR1 (0.92) | SIGMAR1HTR2CQDPRHTR2AHTR6 | |
| SCHEMBL894220 | 0.79 | QDPR (0.60) | SIGMAR1HTR2CQDPRHTR6 | |
| Hydrochloric Acid SCHEMBL29923085 | 0.79 | PRMT5 (0.62) | SIGMAR1HTR2CQDPRHTR6 | |
| Hydrochloric Acid SCHEMBL6739875 | 0.77 | HTR2C (0.61) | SIGMAR1HTR2CQDPRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642262-B2 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2010-01-05 | — | — | US | disclosed |
| US-20050101610-A1 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-0755923-B1 | Ameliorant or remedy for symptoms caused by Ischemic diseases and Phenylpiperidine compounds useful therefor | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
| EP-0958280-B1 | ARYLPIPERIDINOPROPANOL AND ARYLPIPERAZINOPROPANOL DERIVATIVES AND PHARMACEUTICALS CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
| US-6838470-B2 | Arylpiperidinopropanol and arylpiprazinopropanol derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1138678-B1 | Process for making N-((4-phenyl) methylphenyl) piperazines | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6525199-B1 | Ring coupling, reduction and deprotecting; synthesis of compounds for alleviation and treatment of symptoms due to ischemic diseases | SUNTORY LIMITED (JP) | 2003-02-25 | — | — | US | disclosed |
| US-6469010-B1 | COMPOSITION ALSO FOR ALLEVIATION OR TREATMENT OF SYMPTOMS DERIVED FROM SEIZURES, EPILEPSY AND MIGRAINE HEADACHES, AND SUPPRESSION OF CALCIUM ION OVERLOAD | SUNTORY LIMITED (JP) | 2002-10-22 | — | — | US | disclosed |
| US-6407099-B1 | SUPPRESSING CYTOTOXIC CALCIUM OVERLOAD AND LIPID PEROXIDATION; ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIEDEMIC AGENTS; BRAIN, NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-0757986-B1 | Arylpiperidine and arylpiperazine derivatives and drugs containing the same | SUNTORY LTD (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-1138678-A2 | Process for making N-((4-phenyl) methylphenyl) piperazines | SUNTORY LIMITED (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6048876-A | ANTICONVULSANTS; ANTIEPILEPIC AGENT | SUNTORY LIMITED (JP) | 2000-04-11 | — | — | US | disclosed |
| US-5723475-A | Arylpiperidine and arylpiperazine derivatives and medicament containing the same | SUNTORY LIMITED (JP) | 1998-03-03 | — | — | US | disclosed |
| US-5631401-A | Inhibitors of protein farnesyltransferase and squalene synthase | ABBOTT LABORATORIES (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0757986-A1 | ARYLPIPERIDINE AND ARYLPIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0755923-A1 | AMELIORANT OR REMEDY FOR SYMPTOMS CAUSED BY ISCHEMIC DISEASES AND COMPOUNDS USEFUL THEREFOR | SUNTORY LIMITED (JP) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995021815-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND SQUALENE SYNTHASE | ABBOTT LABORATORIES (US) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | NR1H2, NR1H3, APOL1 | SIGMAR1 351/4885HTR2C 1370/4885QDPR 2304/4885 |
| US-20050101610-A1 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | NR1H2, NR1H3, NR3C2 | SIGMAR1 464/4885HTR2C 1743/4885QDPR 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.